Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Sold by Epoch Investment Partners Inc.

Epoch Investment Partners Inc. decreased its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.2% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 405,715 shares of the company’s stock after selling 731 shares during the period. Epoch Investment Partners Inc.’s holdings in Medpace were worth $167,094,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. FORA Capital LLC bought a new stake in Medpace during the first quarter worth approximately $2,222,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Medpace in the 1st quarter worth $5,179,000. Eagle Asset Management Inc. lifted its holdings in shares of Medpace by 155.0% in the fourth quarter. Eagle Asset Management Inc. now owns 226,435 shares of the company’s stock valued at $69,409,000 after buying an additional 137,632 shares during the period. Evoke Wealth LLC bought a new position in Medpace during the fourth quarter valued at about $3,149,000. Finally, Norden Group LLC boosted its stake in Medpace by 488.0% during the first quarter. Norden Group LLC now owns 29,480 shares of the company’s stock valued at $11,914,000 after buying an additional 24,466 shares in the last quarter. 77.98% of the stock is owned by institutional investors and hedge funds.

Medpace Price Performance

NASDAQ MEDP opened at $365.70 on Friday. The firm has a market capitalization of $11.33 billion, a price-to-earnings ratio of 37.28, a price-to-earnings-growth ratio of 1.74 and a beta of 1.35. The company has a 50 day simple moving average of $378.15 and a 200-day simple moving average of $391.95. Medpace Holdings, Inc. has a 52-week low of $227.21 and a 52-week high of $459.77.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, July 22nd. The company reported $2.75 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.54 by $0.21. Medpace had a net margin of 16.74% and a return on equity of 55.14%. The company had revenue of $528.10 million during the quarter, compared to analyst estimates of $528.41 million. During the same quarter last year, the business posted $1.93 EPS. The company’s revenue for the quarter was up 14.6% on a year-over-year basis. On average, analysts predict that Medpace Holdings, Inc. will post 11.66 EPS for the current year.

Analysts Set New Price Targets

MEDP has been the subject of a number of research analyst reports. Guggenheim cut their price target on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a report on Wednesday, July 24th. StockNews.com lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Wednesday. Robert W. Baird decreased their price target on shares of Medpace from $430.00 to $413.00 and set an “outperform” rating on the stock in a research report on Friday. Deutsche Bank Aktiengesellschaft cut their price objective on Medpace from $395.00 to $336.00 and set a “hold” rating for the company in a research report on Wednesday, July 24th. Finally, Mizuho initiated coverage on Medpace in a report on Tuesday, May 28th. They issued a “buy” rating and a $435.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $420.88.

About Medpace

Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.